Showing results (71-80 of 131) with videos related to
Sort By:
Pageof 14
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 18, 2017
The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studiesMark S Freedman, Jerry S Wolinsky, Giancarlo Comi, et al.Annals of Neurology|August 30, 2018
Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trialJerry S Wolinsky, Xavier Montalban, Stephen L Hauser, et al.Neuroimage. Clinical|November 2, 2013
Regional cortical thickness in relapsing remitting multiple sclerosis: A multi-center studyPonnada A Narayana, Koushik A Govindarajan, Priya Goel, et al.The Lancet. Neurology|September 7, 2014
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trialAaron E Miller, Jerry S Wolinsky, Ludwig Kappos, et al.Neurology(R) Neuroimmunology & Neuroinflammation|September 13, 2019
Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MSEdward J Fox, Fred D Lublin, Jerry S Wolinsky, et al.Brain : a Journal of Neurology|September 10, 2019
Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosisColm Elliott, Shibeshih Belachew, Jerry S Wolinsky, et al.The New England Journal of Medicine|May 11, 2019
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple SclerosisXavier Montalban, Douglas L Arnold, Martin S Weber, et al.Multiple Sclerosis and Related Disorders|June 14, 2019
Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study<sup>★★</sup>Aaron E Miller, Patrick Vermersch, Ludwig Kappos, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|June 14, 2019
Brain and lesion segmentation in multiple sclerosis using fully convolutional neural networks: A large-scale studyRefaat E Gabr, Ivan Coronado, Melvin Robinson, et al.Journal of Neurology|March 2, 2019
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosisBenjamin Turner, Bruce A C Cree, Ludwig Kappos, et al.Pageof 14